Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 347

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

Open access
Karikari, Thomas K., Benedet, Andréa L., Ashton, Nicholas J., Lantero Rodriguez, Juan, Snellman, Anniina, Suárez-Calvet, Marc, Saha-Chaudhuri, Paramita, Lussier, Firoza, Kvartsberg, Hlin, Rial, Alexis Moscoso, Pascoal, Tharick A., Andreasson, Ulf, Schöll, Michael, Weiner, Michael W., Rosa-Neto, Pedro, Trojanowski, John Q., Shaw, Leslie M., Blennow, Kaj, Zetterberg, Henrik, for the Alzheimer’s Disease Neuroimaging Initiative · 2021 · Molecular Psychiatry

Abstract

Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer’s disease (AD), their broad implementation in clinical and trial settings are restricted by high cost and limited accessibility. Plasma phosphorylated-tau181 (p-tau181) is a promising blood-based biomarker that is specific for AD, correlates with cerebral Aβ and tau pathology, and predicts future cognitive decline. In this study, we report the performance of p-tau181 in >1000 individuals from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), including cognitively unimpaired (CU), mild cognitive impairment (MCI) and AD dementia patients characterized by Aβ PET. We confirmed that plasma p-tau181 is increased at the preclinical stage of Alzheimer and further increases in MCI and AD dementia. Individuals clinically classified as AD dementia but having negative Aβ PET scans show little increase but plasma p-tau181 is increased if CSF Aβ has already changed prior to Aβ PET changes. Despite being a multicenter study, plasma p-tau181 demonstrated high diagnostic accuracy to identify AD dementia (AUC = 85.3%; 95% CI, 81.4–89.2%), as well as to distinguish between Aβ− and Aβ+ individuals along the Alzheimer’s continuum (AUC = 76.9%; 95% CI, 74.0–79.8%). Higher baseline concentrations of plasma p-tau181 accurately predicted future dementia and performed comparably to the baseline prediction of CSF p-tau181. Longitudinal measurements of plasma p-tau181 revealed low intra-individual variability, which could be of potential benefit in disease-modifying trials seeking a measurable response to a therapeutic target. This study adds significant weight to the growing body of evidence in the use of plasma p-tau181 as a non-invasive diagnostic and prognostic tool for AD, regardless of clinical stage, which would be of great benefit in clinical practice and a large cost-saving in clinical trial recruitment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-020-00923-z

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 347

Metadata

Authors
Karikari, T. K., Benedet, A. L., Ashton, N. J., Lantero Rodriguez, J., Snellman, A., Suárez-Calvet, M., Saha-Chaudhuri, P., Lussier, F., Kvartsberg, H., Rial, A. M., Pascoal, T. A., Andreasson, U., Schöll, M., Weiner, M. W., Rosa-Neto, P., Trojanowski, J. Q., Shaw, L. M., Blennow, K., Zetterberg, H., & Initiative, F. T. A. D. N.
Venue
Molecular Psychiatry
Published
2020-10-26
Volume
26
Issue
2
Pages
429-442
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W3093943691
Cited by
347
References
50
FWCI
33.35
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative. https://app.cochat.ai/papers/10.1038/s41380-020-00923-z
The paper
Karikari, T. K., Benedet, A. L., Ashton, N. J., Lantero Rodriguez, J., Snellman, A., Suárez-Calvet, M., Saha-Chaudhuri, P., Lussier, F., Kvartsberg, H., Rial, A. M., Pascoal, T. A., Andreasson, U., Schöll, M., Weiner, M. W., Rosa-Neto, P., Trojanowski, J. Q., Shaw, L. M., Blennow, K., Zetterberg, H., & Initiative, F. T. A. D. N. (2021). Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative. Molecular Psychiatry. https://doi.org/10.1038/s41380-020-00923-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.